Submitted by Anonymous (not verified) on 21 October 2025 - 10:25
Opinion/decision on a Paediatric investigation plan (PIP): Nucala, Mepolizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0367/2024
Source: